NCT02241057

Brief Summary

This is an open-label study. A total of approximately 60 subjects will be randomly assigned to receive either the heat patch (30 subjects) with a temperature probe/skin reference probe or a heat patch (30 subjects) alone. The study will consist of 2 visits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Sep 2014

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

September 11, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 16, 2014

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

March 17, 2017

Status Verified

January 1, 2016

Enrollment Period

Same day

First QC Date

September 11, 2014

Last Update Submit

March 15, 2017

Conditions

Keywords

temperature profileair activated 3-cell patchadhesion

Outcome Measures

Primary Outcomes (2)

  • Patch Temperature

    The temperature of the patch will be monitored by the use of a probe placed under the patch and recorded for the duration of the study.

    8 hours

  • Patch Adhesion

    Patch adhesion will be recorded for the duration of the study.

    8 hours

Study Arms (2)

Temperature

EXPERIMENTAL

Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear

Device: Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)Other: Temperature Probe

Adhesion

EXPERIMENTAL

Evaluate the adhesion with and without the presence of a temperature probe

Device: Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Interventions

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects who complete an appropriately administered informed consent process that includes signing the consent form.
  • Subjects 18-75 years old of either sex.
  • Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
  • Subjects who are in good general health.
  • Subjects who are willing and able to have the test products applied as directed, and comply with study instructions.
  • Participants must be willing to restrict their activity for the 8 hour patch wear time.
  • All participants agree to wear a t-shirt provided by the site for the entire 8 hour patch wear time.

You may not qualify if:

  • Subjects who have a history of sensitivity to any of the test products or adhesion material.
  • Subjects who are pregnant.
  • Subject with excessive hair at the application sites, scar tissue, tattoo, or coloration that would interfere with placement of test product or skin assessment.
  • Subjects with diabetes, rheumatoid arthritis, poor circulation or have any clinically significant chronic illness.
  • Subjects with active dermatitis (including sunburn) in the treatment area, or other visible dermatological disease which, in the investigator's opinion, might interfere with the response to the test products or interfere with the skin assessments associated with the test products.
  • Have history of significant dermatologic cancers (eg, melanoma, squamous cell carcinoma).
  • Subjects who have used topical dermatological products in the application area within 24 hours prior to the test product application.
  • Subject using a concomitant medication that, in the investigator's opinion, could interfere with the interpretation of study results. Examples of such drugs include non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin), topical or systemic corticosteroids, and cold/cough products containing antihistamines and/or either phentolamine, pseudoephedrine or phenylpropanolamine.
  • Subjects who have received an investigational medication or device within 30 days prior to enrolment into this study.
  • Subjects who are currently participating in an investigational study.
  • Subject who are known to be noncompliant or are unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wilkins Research

Chattanooga, Tennessee, 37421, United States

Location

MeSH Terms

Conditions

Tissue Adhesions

Condition Hierarchy (Ancestors)

CicatrixFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ellen Bonagua, MD

    Chattem, Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2014

First Posted

September 16, 2014

Study Start

September 1, 2014

Primary Completion

September 1, 2014

Study Completion

October 1, 2014

Last Updated

March 17, 2017

Record last verified: 2016-01

Data Sharing

IPD Sharing
Will not share

Locations